Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Near-Term+Volatility+Expected+on+Exec+Shift%2C+But+Fundamentals+Inact+for+Synta+Pharma+%28SNTA%29+-+Roth/9241863.html for the full story.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that Safi R. Bahcall, Ph.D., has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective immediately, and has been replaced by a newly formed...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the launch of
GANNET53, a pan-European randomized trial evaluating the combination of
ganetespib and paclitaxel vs. paclitaxel alone in over 200 patients with
When a woman, claiming to be the wife of a deceased general from Nigeria, writes to us saying she needs our help getting $10 million out of the country and in return we’ll get 20% of the money, most of us know that’s a load of bull.
ByChristopher F. Davis:
Cancer is a disease that has impacted the lives of each and every one of us. Cancer is a disease that involves unregulated cell growth, where cells divide and grow uncontrollably, forming malignant tumors, and can...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the
appointment of Steven Bernitz as Senior Vice President, Corporate
Development. Mr. Bernitz brings over 20 years' experience in corporate
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Synta Pharmaceuticals (SNTA):